BioSpecifics Technologies Corp. has been granted U.S. patent No.5,173,295 for a collagenase enzyme "nerve glue" to reduce thedamaging effects of injury or surgery, as well as promote fasterhealing with less permanent damage to affected nerves.
The Lynbrook, N.Y., company's (NASDAQ:BSTC) principleproduct, FDA-approved Collagenase ABC (Santyl) used in topicalapplications for skin ulcers and severe burns, has received aclinical trial exemption in England. The company will beginclinical trials for marketing approval in the United Kingdom.
Initial clinical trials of collagenase ointment in the treatment ofdeep second-degree burns has been expanded to four burncenters after the initial clinical trials were done at StonybrookUniversity, New York.
(c) 1997 American Health Consultants. All rights reserved.